Mok TS, Kim D, Wu Y, et al. Overall Survival (OS) for First-Line Crizotinib Versus Chemotherapy in ALK+ Lung Cancer: Updated Results from PROFILE 1014. ESMO 2017, abstract LBA50.
Circulerend tumor-DNA toont maanden eerder dan scan of kankertherapie effectief is
nov 2023 | Dermato-oncologie, Uro-oncologie